Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–55.

Article  PubMed  Google Scholar 

European Association for Study of Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48(5):599–641.

Article  Google Scholar 

Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–93. https://doi.org/10.1016/j.jhep.2021.11.018.

Article  PubMed  Google Scholar 

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. https://doi.org/10.1016/j.jhep.2018.03.019.

Article  Google Scholar 

Llovet JM, Real MI, Montaña X, et al. Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–9.

Article  PubMed  Google Scholar 

Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429–42.

Article  CAS  PubMed  Google Scholar 

Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46:474–81.

Article  CAS  PubMed  Google Scholar 

Lencioni R, de Baere T, Burrel M, et al. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC bead (DEBDOX): technical recommendations. Cardiovasc Interv Radiol. 2012;35(5):980–5.

Article  Google Scholar 

Xie ZB, Wang XB, Peng YC, et al. Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. Hepatol Res. 2015;45:190–200.

Article  CAS  PubMed  Google Scholar 

Sacco R, Bargellini I, Bertini M, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol JVIR. 2011;22:1545–52.

Article  PubMed  Google Scholar 

Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111:255–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malagari K, Pomoni M, Moschouris H, et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Interv Radiol. 2012;35:1119–28.

Article  Google Scholar 

Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol. 2010;33:41–52.

Article  Google Scholar 

Cersosimo RJ. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma. Am J Health Syst Pharm. 2021;78:187–202.

Article  PubMed  Google Scholar 

Contratto M, Wu J. Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma. World J Gastrointest Oncol. 2018;10:108–14.

Article  PubMed  PubMed Central  Google Scholar 

Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.

Article  CAS  PubMed  Google Scholar 

Yau T, Park W, Finn RS, et al. CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30:v874-V875. https://doi.org/10.1093/annonc/mdz394.029.

Article  Google Scholar 

Finn S, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.

Article  CAS  PubMed  Google Scholar 

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1). https://clinicaltrials.gov/ct2/show/NCT03778957.

Nivolumab in combination with TACE/TAE for patients with intermediate stage HCC (TACE-3). https://clinicaltrials.gov/ct2/show/NCT04268888.

Safety and efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in combination with transarterial chemoembolization (TACE) in participants with incurable/non-metastatic hepatocellular carcinoma (MK-7902-012/E7080-G000-318/LEAP-012). https://clinicaltrials.gov/ct2/show/NCT04246177.

Fuchs K, Bize PE, Dormond O, et al. Drug-eluting beads loaded with antiangiogenic agents for chemoembolization: in vitro sunitinib loading and release and in vivo pharmacokinetics in an animal model. J Vasc Interv Radiol. 2014;25(3):379–87.

Article  PubMed  Google Scholar 

Argyros O, Karampelas T, Varela A, et al. Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule. Oncotarget. 2017;8(23):37250–62.

Article  PubMed  PubMed Central  Google Scholar 

Jordan O, Denys A, De Baere T, Boulens N, Doelker E. Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan. J Vasc Interv Radiol. 2010;21(7):1084–90.

Article  PubMed  Google Scholar 

Raoul J-L, Forner A, Bolondi L, et al. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28–36.

Article  CAS  PubMed  Google Scholar 

Kang YJ, Lee BC, Kim JK, Yim NY, Kim HO, Cho SB, Jeong YY. Conventional versus small doxorubicin-eluting bead transcatheter arterial chemoembolization for treating barcelona clinic liver cancer stage 0/A hepatocellular carcinoma. Cardiovasc Interv Radiol. 2020;43(1):55–64.

Article  Google Scholar 

Lewis AL, Gonzalez MV, Lloyd AW, et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol. 2006;17(2 Pt 1):335–42.

Article  PubMed  Google Scholar 

Abdekhodaie MJ, Wu XY. Drug loading onto ion-exchange microspheres: modeling study and experimental verification. Biomaterials. 2006;27(19):3652–62.

CAS  PubMed  Google Scholar 

Gonzalez MV, Tang Y, Phillips GJ, et al. Doxorubicin eluting beads-2: methods for evaluating drug elution and in-vitro:in-vivo correlation. J Mater Sci Mater Med. 2008;19(2):767–75.

Article  CAS  PubMed  Google Scholar 

Al-Abd AM, Aljehani ZK, Gazzaz RW, Fakhri SH, Jabbad AH, Alahdal AM, Torchilin VP. Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors. J Control Release. 2015;10(219):269–77.

Article  Google Scholar 

Forster RE, Tang Y, Bowyer C, et al. Development of a combination drug-eluting bead: towards enhanced efficacy for locoregional tumour therapies. Anticancer Drugs. 2012;23(4):355–69.

Article  CAS  PubMed  Google Scholar 

Ranieri G, Ammendola M, Marech I, et al. Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients. World J Gastroenterol. 2015;21(19):6018–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liang B, Zheng CS, Feng GS, et al. Correlation of hypoxia-inducible factor 1alpha with angiogenesis in liver tumors after transcatheter arterial embolization in an animal model. Cardiovasc Interv Radiol. 2010;33(4):806–12.

Article  Google Scholar 

Gupta S, Kobayashi S, Phongkitkarun S, Broemeling LD, Kan Z. Effect of transcatheter hepatic arterial embolization on angiogenesis in an animal model. Invest Radiol. 2006;41(6):516–21.

Article  PubMed  Google Scholar 

Rhee TK, Young JY, Larson AC, et al. Effect of transcatheter arterial embolization on levels of hypoxia-inducible factor-1alpha in rabbit VX2 liver tumors. J Vasc Interv Radiol. 2007;18(5):639–45.

Article  PubMed  Google Scholar 

Deudero JJ, Caramelo C, Castellanos MC, et al. Induction of hypoxia-inducible factor-1alpha gene expression by vascular endothelial growth factor. J Biol Chem. 2008;283(17):11435–44.

Article  CAS  PubMed  Google Scholar 

Chung YH, Han G, Yoon JH, et al. Interim analysis of START: study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. Int J Cancer. 2013;132(10):2448–58.

Article  CAS  PubMed  Google Scholar 

Fuchs K, Bize PE, Denys A, Borchard G, Jordan O. Sunitinib-eluting beads for chemoembolization: methods for in vitro evaluation of drug release. Int J Pharm. 2015;482(1–2):68–74.

Article  CAS  PubMed  Google Scholar 

Hagan A, Phillips GJ, Macfarlane WM, Lloyd AW, Czuczman P, Lewis AL. Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies. Eur J Pharm Sci. 2017;1(101):22–30.

Article  Google Scholar 

Lee KH, Liapi EA, Cornell C, et al. Doxorubicin-loaded QuadraSphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer. Cardiovasc Interv Radiol. 2010;33(3):576–82.

Article  Google Scholar 

Benjamin RS, Riggs CE Jr, Bachur NR. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res. 1977;37(5):1416–20.

CAS  PubMed  Google Scholar 

Laubrock N, Hempel G, Schulze-Westhoff P, et al. The stability of doxorubicin and ldarubicin in plasma and whole blood. Chromatographia. 2000;52:9–13.

Article  CAS